Billiontoone (NASDAQ:BLLN) Price Target Raised to $125.00 at JPMorgan Chase & Co.

Billiontoone (NASDAQ:BLLN) had its price target upped by equities researchers at JPMorgan Chase & Co. from $120.00 to $125.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 37.63% from the company’s current price.

Several other research firms have also weighed in on BLLN. Guggenheim cut their target price on shares of Billiontoone from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Wells Fargo & Company cut their target price on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d)” rating on shares of Billiontoone in a report on Friday, May 1st. Finally, BTIG Research dropped their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $122.43.

Billiontoone Stock Up 11.6%

BLLN stock traded up $9.43 during midday trading on Thursday, reaching $90.83. The company’s stock had a trading volume of 926,306 shares, compared to its average volume of 338,266. Billiontoone has a 52 week low of $61.96 and a 52 week high of $138.70. The stock has a market capitalization of $4.18 billion and a PE ratio of 427.67. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.32 and a current ratio of 11.69. The stock’s 50-day moving average price is $77.51.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. Billiontoone’s revenue was up 83.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.39) earnings per share. As a group, equities analysts forecast that Billiontoone will post 0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLLN. Rossby Financial LCC acquired a new stake in Billiontoone in the 4th quarter valued at $25,000. Wells Fargo & Company MN acquired a new stake in Billiontoone in the 4th quarter valued at $76,000. Smartleaf Asset Management LLC acquired a new stake in Billiontoone in the 4th quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Billiontoone in the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC acquired a new stake in Billiontoone in the 4th quarter valued at $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.